Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictability of Initial Risperidone Response in Anxiety
NCT03227562Phase 3Terminated
- Start
- Sep 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of risperidone in anxiety disorder (2 arms). Primary endpoint: Anxiety (Hospital Anxiety Depression Scale) at Week 12. Started Sep 2017; status: terminated.
02
Drugs
risperidone
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT03227562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227562.